U.S. markets close in 12 minutes

RedHill Biopharma Ltd. (RDHL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.23+0.25 (+4.18%)
As of 3:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close5.98
Open6.01
Bid6.20 x 800
Ask6.25 x 800
Day's Range6.00 - 6.33
52 Week Range5.91 - 11.52
Volume124,021
Avg. Volume402,767
Market Cap290.737M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-2.09
Earnings DateMar 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Could These 2 Exciting COVID Stocks be 10-Baggers?
    Motley Fool

    Could These 2 Exciting COVID Stocks be 10-Baggers?

    If you're looking for a stock with potential to rise 1,000%, you might find it in the coronavirus vaccine and treatment space. Let's take a look at two exciting players working on coronavirus treatments -- and see if they have what it takes to become tomorrow's stock-market winners. Humanigen (NASDAQ: HGEN) shares soared more than 54% in one trading session after the company reported positive results from its investigational monoclonal antibody treatment for hospitalized COVID-19 patients.

  • RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
    PR Newswire

    RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a fourth independent Data Safety Monitoring Board (DSMB) safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 255 patients treated for 14 days, extending the total opaganib safety database to approximately 380 patients.

  • RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals
    PR Newswire

    RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AztraZeneca AB and AstraZenca Pharmaceuticals LP ("AZ") and Nektar Therapeutics ("Nektar") have entered into a settlement and license agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories PVT. LTD. ("MSN") resolving their patent litigation in the U.S. in response to MSN's Abbreviated New Drug Application ("ANDA") seeking approval by the US. Food and Drug Administration ("FDA") to market a generic version of Movantik® (naloxegol).